Sponsor or Organizer: Cambridge Healthtech Institute

Description: Focusing on Two Interrelated Topics:  De-Risking Drug Development Decision Making  Novel Paradigms that Can Positively Impact Drug Development

Program Features:  Will Systems Biology Improve Decision Making?  How Can Changes in the R&D Business Model Enable Better Risk Management?  The Use of Portfolio Management, Therapeutic Area Strategy and Biomarkers to Reduce Attrition in Drug Development  Future Strategic Models of Portfolio Management  Tangibly Impacting the Predictability of Preclinical and Clinical Testing  Addressing Bottlenecks within the NCE and NBE Discovery Process  Making Better Decisions with Imperfect Data  Novel Approaches to Reducing the Costs of Attrition

Dates: 01/30/2006

Location: Orlando, FL, USA